Vertex Pharmaceuticals (VRTX)
$490.32
5.59 (1.13%)
VRTX Stock Quote Delayed 30 Minutes
Biggest Movers in Healthcare Stocks Now – PBYI CRL QCOR
Healthcare stocks declined on Wall Street on Friday, down 1.7%. NYSE:PBYI, NASDAQ:PODD, NASDAQ:IPXL, NYSE:CRL, NASDAQ:QCOR, NASDAQ:NKTR, NASDAQ:HTWR, NYSE:EXAM, NASDAQ:PRXL, NASDAQ:VRTX, NYSE:CVD
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
127.20B
PE Ratio
31.82
EPS
15.41
Volume (Avg. Vol.)
821,276
Day's Range
$487.98 - $495.35
52-Week Range
$340.20 - $498.77
Dividend & Yield
N/A (N/A)
VRTX Stock Predictions, Articles, and Vertex Pharmaceuticals News
9 Biotech Buyout Players to Watch
The deal between Human Genome Sciences and GlaxoSmithKline is just the most recent of big pharma buyouts -- and these biotech players could be next.
Top 6 Stocks to Buy for July
This month’s emphasis is on stocks that should do well despite near-term market concerns.
7 Biotech Stocks to Add to Your Portfolio
The biotech business is working overtime to find the next breakthrough drugs and treatments for a population that gets older every day.
7 Biotech Stocks to Buy
With an aging U.S. population in need of healthcare, biotech stocks will grow with the demographic, providing an excellent chance to buy these 7 stocks.
Amazon Skewered After Hours — Tuesday’s IP Market Recap
And Netflix, RadioShack got beat up during the day.
RIMM Completes a Week of Gloomy Outlooks — Friday’s IP Market Recap
Research In Motion joined Intel, Best Buy and First Solar in forecasting leaner times ahead. Here's a look at RIM, as well as other big news from this week.
Dreary Day for Gold, Oil — Wednesday’s IP Market Recap
Gold breaks through its key $1,600 per ounce level
Merck CEO Pledges Drug Pipeline Will Yield Results in Both Short and Long Term
Merck CEO Kenneth Frazier acknowledges company's lagging stock, touts potential of numerous drugs in late development stages.
